China’s CICC Capital reached a CNY4.2b (approximately USD648m) second close of its Qide Innovation Biopharmaceutical Equity Investment Fund, backed by China’s state-owned enterprises, corporations, and high-net-worth individuals. Read more… Read More
CITIC Capital has invested an undisclosed amount in Max-Inf, a China-based provider of baby travel safety systems. Read more… Read More
ABC World Asia, an Asia-focused fund managed by Temasek Holdings, led a USD20m Series C for CropIn, an Indian AI- and data-based agtech, with participation from CDC Group and Kris Gopalakrishnan’s family office Pratithi Investment Trust, and follow-on from Chiratae Ventures, Invested Development, and Ankur Capital. Read… Read More
A91 Partners has invested USD30m in La Renon, an India-based pharmaceuticals company backed by Sequoia Capital, for a reported 5-6% stake. Read more… Read More
Accial Capital has invested USD21m in debt in Pintek, an Indonesia-based fintech platform that provides credit to students and their families, educational institutions, and their suppliers. Read more… Read More
Philippine mobile wallet GCash has raised more than USD175m from Bow Wave Capital Management. Bow Wave now has a 14% stake in Mynt, which operates GCash. Read more… Read More
Horizons Ventures and Alpha JWC led a USD25m Series A for Indonesia-based digital investment platform Ajaib Group, with follow-on from SoftBank Ventures Asia, Insignia Ventures, and Y Combinator. Read more… Read More
KKR has reached a USD3.9b final close for its KKR Asia Pacific Infrastructure Investors fund. The vehicle will focus on infrastructure-related investments across Asia Pacific. Read more … Read More
The Carlyle Group led a USD123m Series D for China-based biotech firm Abbisko, with participation from Warburg Pincus, OrbiMed, and Lake Bleu Capital. Janchor Partners, Sage Partners, SHC, and Greater Bay Area Homeland Development Fund also participated in the round, and existing investors Lilly Asia Ventures, Temasek Holdings,… Read More
Sequoia Capital China led a USD150m Series B for China-based biotech firm Visen Pharmaceuticals, with participation from OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital, and CDG Capital, as well as follow-on from existing investors, including Ascendis Pharma A/S, Vivo Capital, and… Read More
(default archive template)